Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01919216 · ClinicalTrials.gov registry record · Phase 4
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT01919216 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 65 participants.
The verdict
NCT01919216, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
Studies of the neural mechanisms underlying placebo effects in antidepressant clinical trials largely have been limited to demonstrating objective differences in brain activity between responders and non-responders to placebo. This 8 week Placebo-controlled and Open groups study employs a novel antidepressant trial design with integrated functional magnetic resonance imaging (fMRI) to manipulate patient expectancy and examine its neural mediators.
Interventions
- DRUG Citalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2010-01 |
| Est. Completion | 2016-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01919216
The ClinicalTrials.gov registry entry for NCT01919216 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Citalopram is the first listed.
NCT01919216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01919216 about?
NCT01919216 is a clinical study titled "Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms". Studies of the neural mechanisms underlying placebo effects in antidepressant clinical trials largely have been limited to demonstrating objective differences in brain activity between responders and non-responders to placebo. This 8 week Placebo-controlled and Open groups study employs a novel anti...
What is the current status of trial NCT01919216?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2010-01. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01919216?
The interventions under investigation include: Citalopram (DRUG).
Who is sponsoring clinical trial NCT01919216?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.